Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tyligand Bioscience (Shanghai) Limited currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. The prosecution is split between 2 distinct examiners and 2 distinct art units. The 2 distinct art units suggest that the company's biotechnology research is classified into multiple technical areas, indicating a variety of filings. The assigned art units represent the total count of such divisions involved in the company's current prosecution.
COLEMAN, BRENDA LIBBY is the busiest examiner, managing 1 busiest examiner pending office action. Since there are 2 pending office actions and 2 distinct examiners, the workload is distributed among the assigned staff. The 1 busiest examiner pending office action indicates the current level of activity for the busiest examiner. The distinct examiners confirm that the prosecution is shared across different individuals at the office.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290604 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | COLEMAN, BRENDA LIBBY | 16d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290604 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | COLEMAN, BRENDA LIBBY | 16d |
| 18032663 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | VANHORN, ABIGAIL LOUISE | 22d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18290604 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | COLEMAN, BRENDA LIBBY | 1624 | §102§112Other | Non-Final OA | 16d | Pending | Jan 19, 2024 |
| 18032663 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | VANHORN, ABIGAIL LOUISE | 1636 | §103 | Non-Final OA | 22d | Pending | Apr 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial